App-Quantinova.ai

A model for predicting individualized absolute risk of contralateral breast cancer.

Marzana Chowdhury - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Are racial differences in obesity and insulin resistance related to aggressive breast cancer?

Emily Gallagher - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

The impact of long-standing metformin use on survival in breast cancer patients.

Yun Rose Li - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Metformin Hydrochloride

Treatment and outcomes from a large, prospective, national longitudinal cohort study of screen detected ductal carcinoma in situ (DCIS).

Alastair Mark Thompson - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Risk of arterial thromboembolism in patients with colorectal cancer.

Babak B. Navi - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Myocardial infarction

N/A

Impact of surgery vs. other treatments in carcinosarcoma of the lung: A Surveillance, Epidemiology, and End Results (SEER) Analysis.

Alexander Howard - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

Rethinking the Hispanic advantage in cancer outcomes: Influence of birthplace.

Paulo Pinheiro - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

NHL risk in HIV+ adults on antiretroviral therapy in four continents.

Eliane Rohner - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Acquired immunodeficiency syndrome

N/A

Evaluating genetic and genomic sequencing knowledge from parents and young adult cancer survivors.

Trisha Ali-Shaw - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Detection of somatic variants in peripheral blood lymphocytes using a 25-gene hereditary cancer panel.

Bradford Coffee - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Identification of clinically actionable pharmacogenetic variants during tumor genetic profiling in pediatric cancer patients.

Daniel Louis Hertz - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

BRCA testing among Medicare beneficiaries with breast cancer from 2011 to 2013.

Brygida Berse - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Universal BRCA testing of TNBC and HGSOC and active family outreach to increase identification of at-risk relatives for cascade testing.

Kimberly I. Muse - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

High grade serous ovarian cancer

N/A

The heritability of retinoblastoma: An institutional review.

Michael Francis Walsh - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Retinoblastoma

N/A

Variant classifications in BRCA1 and BRCA2: A systematic analysis of interlaboratory concordance

Stephen E Lincoln - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

Adjuvant temozolomide for low grade gliomas: Molecular and radiographic correlates of treatment response in a phase II clinical trial.

Michael Traut Wahl - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Low-grade gliomas

Temozolomide

ANG1005, a novel brain-penetrant taxane derivative, for the treatment of recurrent brain metastases and leptomeningeal carcinomatosis from breast cancer.

Priya Kumthekar - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Leptomeningeal Metastasis

Trastuzumab

Impact of EGFR and ALK mutation on the outcomes of non-small cell lung cancer (NSCLC) patients with brain metastases.

Suresh Kumar Balasubramanian - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

Benefit of MGMT methylation in glioblastoma in relation to hTERT promoter mutation.

Huy Tram N Nguyen - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

N/A

An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG oncology/RTOG 0525 and 0825.

Haley R Gittleman - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

N/A

Filters

255783 Abstracts